Thoughts on the timing of targeted therapy initiation for thyroid cancer
10.3760/cma.j.cn321828-20230523-00145
- VernacularTitle:关于甲状腺癌靶向药物治疗启动时机的思考
- Author:
Ying DING
1
;
Li ZHANG
;
Yu LIU
;
Yinqian DENG
;
Huanyu CHEN
;
Xiaoli LAN
;
Wei CAO
Author Information
1. 华中科技大学同济医学院附属协和医院核医学科、分子影像湖北省重点实验室、生物靶向治疗教育部重点实验室，武汉 430022
- Keywords:
Thyroid neoplasms;
Drug therapy;
Protein kinase inhibitors;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(8):504-507
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of persistent/recurrent and metastatic thyroid cancer and medullary thyroid cancer has made significant progress through the use of molecule-targeted therapy. While this approach has shown promise in improving patient outcomes and clinical symptoms, it also carries potential risks. The primary focus and challenge of targeted therapy is to optimize benefits while managing risks within predetermined thresholds. This review examines current targeted treatment practices in thyroid cancer and investigates the correlation between the timing of targeted therapy initiation and the patient benefits, aiming to lay the groundwork for subsequent research.
